Physician profile
Thomas Whitesell
NPI 1245231984
$13,134.05
in general payments reported to CMS, 2019-2025
50 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $912 · 2021: $1,853 · 2022: $1,877 · 2023: $2,277 · 2024: $2,083 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,473 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,472.68 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,385.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,271.93 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $1,091.92 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,047.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $854.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $804.59 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $737.88 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $624.99 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $566.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.91 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $484.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $389.46 | 2019-2023 | Xarelto |
| Insulet Corporation | $270.62 | 2022-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $261.20 | 2019-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Dexcom, INC. | $196.28 | 2021-2025 | Dexcom G6 Transmitter |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Whitesell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.